Breast Cancer Institute

**Adjuvant**

- **HER2+**
  - BRS0115
    - Expanded Access
    - Pertuzumab & Trastuzumab Fixed-Dose Combo in HER2+ Breast Cancer During COVID-19 Pandemic
    - PI: Riaz
    - Pending

- **HER2-**
  - Triple Negative
    - NRGBR003
      - Doxorubicin Hydrochloride and Cyclophosphamide + Paclitaxel + Carboplatin in 3-Neg Breast Cancer
      - PI: Wapnir
      - NRG

- **BRCA+**
  - ECOG-ACRIN-S1418
    - Phase III MK-5475 (Adjuvant TX) Triple Receptor-Negative Breast Cancer After Neoadjuvant Chemotherapy
    - PI: Telli
    - ECOG-ACRIN

- **ER/PR+**
  - BRCA0101
    - Phase III Ribociclib + Endocrine Therapy in Hormone Receptor-Positive HER2-Negative Early Breast Cancer
    - PI: Horst
    - Sponsor: Dana Farber

- **Post mastectomy and reconstructive surgery**
  - BRS0094
    - Radiation Fractionation on Patient Outcomes After Breast REConstruction for Invasive BreastCarcinoma
    - PI: Horst
    - Sponsor: Dana Farber

KEY

- Pending
- Open for Enrollment
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Optional Path
- Enrollment on Hold